Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | F2R | P25116 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | TRHR | P34981 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630560 | 1.00 | OPRK1 (0.46) | OPRK1MEN1KMT2AACEREN | |
| SCHEMBL29630596 | 0.95 | MEN1 (0.43) | OPRK1MEN1KMT2AACEREN | |
| SCHEMBL31384593 | 0.94 | OPRK1 (0.56) | OPRK1ACERENSLC6A2CTSD | |
| SCHEMBL30974302 | 0.93 | SLC6A2 (0.50) | OPRK1RENSLC6A2MC4R | |
| SCHEMBL29630670 | 0.93 | TRHR (0.42) | OPRK1ACESLC6A2TRHR | |
| SCHEMBL30498899 | 0.93 | SLC6A2 (0.42) | OPRK1MEN1KMT2AACEREN | |
| SCHEMBL29925778 | 0.92 | ACE (0.43) | OPRK1MEN1KMT2AACEREN | |
| SCHEMBL30661447 | 0.91 | MC4R (0.45) | OPRK1MEN1KMT2AACEREN | |
| SCHEMBL29555036 | 0.90 | ACE (0.41) | OPRK1MEN1KMT2AACEREN | |
| SCHEMBL29845324 | 0.90 | REN (0.46) | RENSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRK1 4730/4885MEN1 3678/4885KMT2A 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.